ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Cesium carbonate → Methyl 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidine-3-carboxylate

HRID 1410008
ノート
印刷プレビュー

反応式

HRID 1410008 の反応式
Cl[C:2]1[N:3]=[C:4]([NH:11][C:12]2[CH:17]=[CH:16][C:15]([O:18][CH3:19])=[C:14]([O:20][CH3:21])[CH:13]=2)[C:5]2[N:10]=[CH:9][S:8][C:6]=2[N:7]=1.[NH:22]1[CH2:27][CH2:26][CH2:25][CH:24]([C:28]([O:30][CH3:31])=[O:29])[CH2:23]1.C([O-])([O-])=O.[Cs+].[Cs+].CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[CH3:21][O:20][C:14]1[CH:13]=[C:12]([NH:11][C:4]2[C:5]3[N:10]=[CH:9][S:8][C:6]=3[N:7]=[C:2]([N:22]3[CH2:27][CH2:26][CH2:25][CH:24]([C:28]([O:30][CH3:31])=[O:29])[CH2:23]3)[N:3]=2)[CH:17]=[CH:16][C:15]=1[O:18][CH3:19]
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 4

HCID 10796Cesium carbonateHCID 351626Methyl piperidine-3-carboxylateHCID 111557942-Dicyclohexylphosphino-2',4',6'-triisoprophylbiphenylHCID 715341855-chloro-N-(3,4-dimethoxyphenyl)thiazolo[5,4-d]pyrimidin-7-amine

生成物 1

HCID 68379218Methyl 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidine-3-carboxylate収率 56%

試薬・触媒・溶媒 2

HCID 9811564Bis(dibenzylideneacetone)palladium触媒HCID 312751,4-Dioxane溶媒

実験手順

To a solution of (5-chloro-thiazolo[5,4-d]pyrimidin-7-yl)-(3,4-dimethoxy-phenyl)-amine (80 mg, 0.25 mmol) in 10 mL of dioxane, methyl piperidine-3-carboxylate (107 mg, 0.75 mmol), Cs2CO3 (163 mg, 0.50 mmol), X-Phos (47.6 mg, 0.1 mmol) were added. After degassed three times under nitrogen, Pd2(dba)3 (28 mg, 0.05 mmol) was added. The resulting mixture was degassed one more time, and stirred at reflux overnight. The excess of dioxane was removed under reduced pressure and the residue was purified by silica gel chromatography (200-300 mesh, petroleum ether:ethyl acetate=1:1) to give methyl 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidine-3-carboxylate (60 mg, 56%) as an oil, which was solidified after standing overnight. 1H NMR (300 MHz, CDCl3): δ 8.41 (s, 1H), 7.77 (s, 1H), 7.64 (s, 1H), 7.08 (d, 1H, J=9.0 Hz), 6.88 (d, 1H, J=8.7 Hz), 4.92-4.87 (m, 1H), 4.68-4.64 (m, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.71 (s, 3H), 3.30-3.22 (m, 1H), 3.10-3.09 (m, 1H), 2.60-2.59 (m, 1H), 2.11-2.06 (m, 1H), 1.85-1.60 (m, 3H). LC-MS: 430.1 [M+H]+, 452.1 [M+Na]+, tR=1.63 min.

後処理

  1. customAfter degassed three times under nitrogen
  2. customThe resulting mixture was degassed one more time
  3. temperatureat reflux overnight
  4. customThe excess of dioxane was removed under reduced pressure
  5. customthe residue was purified by silica gel chromatography (200-300 mesh, petroleum ether:ethyl acetate=1:1)

出典と根拠

ORDレコード
ord-442c1bcfb77640d7ab0f1e3611d7b952
出典データセット
uspto-grants-2014_12
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08921383B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート